Trial Profile
Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 03 Jun 2020 Results published in the British Journal of Cancer
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.